Related Experiment Video
Updated: Jul 15, 2026
05:28
A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
Does drug-target have a likeness?
Xin Chen1, Ying Fang, Lixia Yao
1College of Life Science, Zhejiang University, Hangzhou, Zhejiang, PR China. xinchen@zju.edu.cn
Methods of Information in Medicine
|May 12, 2007
Summary
We introduce "drug-target likeness," a disease-independent protein property, to simplify genomic-scale drug target screening. This approach uses machine learning to identify potential drug targets from protein sequences, improving therapeutic discovery efficiency.
Area of Science:
- Bioinformatics
- Computational Biology
- Drug Discovery
Background:
- Identifying robust drug targets is challenging and typically disease-dependent.
- Conventional methods require extensive experiments and domain expertise.
- Genomic-scale screening is needed in the post-genomic era.
Purpose of the Study:
- Propose a disease-independent property, "drug-target likeness," for proteins.
- Facilitate genomic-scale screening of potential drug targets.
- Develop a computational approach for target identification.
Main Methods:
- Trained a Support Vector Machine (SVM) classifier.
- Utilized protein sequences from Therapeutic Target Database, DrugBank, and PFam.
- Encoded sequences using residue composition, transition, and distribution features with a Gaussian kernel.
Main Results:
- Achieved 66.4 +/- 5.1% sensitivity and 97.2 +/- 0.6% specificity.
- Reached an overall target prediction accuracy of 94.4 +/- 0.8%.
- Demonstrated SVM's effectiveness in capturing sequence-based features.
Conclusions:
- Drug targets, like small molecules, share sequence features detectable by statistical learning.
- The concept of "drug-target likeness" shows promise for target identification.
- Further research can refine "drug-target likeness" with improved methods and data.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:24Principles of Drug Action
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...